KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Cash from Investing Activities (2016 - 2025)

Emergent BioSolutions (EBS) has 16 years of Cash from Investing Activities data on record, last reported at -$3.9 million in Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 113.64% year-over-year to -$3.9 million; the TTM value through Dec 2025 reached $69.4 million, down 44.57%, while the annual FY2025 figure was $69.4 million, 44.57% down from the prior year.
  • Cash from Investing Activities reached -$3.9 million in Q4 2025 per EBS's latest filing, down from -$3.4 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $257.7 million in Q2 2023 and bottomed at -$271.6 million in Q3 2022.
  • Average Cash from Investing Activities over 5 years is -$9.9 million, with a median of -$13.2 million recorded in 2023.
  • Peak YoY movement for Cash from Investing Activities: crashed 392.03% in 2022, then skyrocketed 902.8% in 2023.
  • A 5-year view of Cash from Investing Activities shows it stood at -$45.8 million in 2021, then increased by 0.87% to -$45.4 million in 2022, then surged by 74.89% to -$11.4 million in 2023, then soared by 350.88% to $28.6 million in 2024, then tumbled by 113.64% to -$3.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were -$3.9 million in Q4 2025, -$3.4 million in Q3 2025, and $17.2 million in Q2 2025.